Association between Insulin Resistance and Breast Carcinoma: A Systematic Review and Meta-Analysis

5.00
Hdl Handle:
http://hdl.handle.net/10757/320267
Title:
Association between Insulin Resistance and Breast Carcinoma: A Systematic Review and Meta-Analysis
Authors:
Hernández, Adrian V. ( 0000-0002-9999-4003 ) ; Guarnizo, Mirella; Miranda, Yony; Pasupuleti, Vinay; Deshpande, Abhishek; Paico, Socorro; Lenti, Hosten; Ganoza, Silvia; Montalvo, Laritza; Thota, Priyaleela; Lazaro, Herbert
Citation:
PLoS ONE 9(6): e99317
Publisher:
Public Library of Science (PLoS)
Journal:
PLoS ONE
Issue Date:
9-Jun-2014
URI:
http://hdl.handle.net/10757/320267
DOI:
10.1371/journal.pone.0099317
Additional Links:
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0099317
Abstract:
Objective: This study was undertaken to evaluate the association between components defining insulin resistance and breast cancer in women. Study Design: We conducted a systematic review of four databases (PubMed-Medline, EMBASE, Web of Science, and Scopus) for observational studies evaluating components defining insulin resistance in women with and without breast cancer. A meta-analysis of the association between insulin resistance components and breast cancer was performed using random effects models. Results: Twenty-two studies (n = 33,405) were selected. Fasting insulin levels were not different between women with and without breast cancer (standardized mean difference, SMD 20.03, 95%CI 20.32 to 0.27; p = 0.9). Similarly, non-fasting/ fasting C-peptide levels were not different between the two groups (mean difference, MD 0.07, 20.21 to 0.34; p = 0.6). Using individual odds ratios (ORs) adjusted at least for age, there was no higher risk of breast cancer when upper quartiles were compared with the lowest quartile (Q1) of fasting insulin levels (OR Q2 vs. Q1 0.96, 0.71 to 1.28; OR Q3 vs. Q1 1.22, 0.91 to 1.64; OR Q4 vs. Q1 0.98, 0.70 to 1.38). Likewise, there were no differences for quartiles of non-fasting/fasting C-peptide levels (OR Q2 vs. Q1 1.12, 0.91 to 1.37; OR Q3 vs. Q1 1.20, 0.91 to 1.59; OR Q4 vs. Q1 1.40, 1.03 to 1.92). Homeostatic model assessment (HOMAIR) levels in breast cancer patients were significantly higher than in people without breast cancer (MD 0.22, 0.13 to 0.31, p, 0.00001). Conclusions: Higher levels of fasting insulin or non-fasting/fasting C-peptide are not associated with breast cancer in women. HOMA-IR levels are slightly higher in women with breast cancer.
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/openAccess
Language:
eng
Description:
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords:
Breast cancer; Insulin; Insulin resistence
EISSN:
1932-6203
Sponsors:
This study was funded by the Instituto Me´dico de la Mujer, Lima, Peru. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Full metadata record

DC FieldValue Language
dc.contributor.authorHernández, Adrian V.spa
dc.contributor.authorGuarnizo, Mirellaspa
dc.contributor.authorMiranda, Yonyspa
dc.contributor.authorPasupuleti, Vinayspa
dc.contributor.authorDeshpande, Abhishekspa
dc.contributor.authorPaico, Socorrospa
dc.contributor.authorLenti, Hostenspa
dc.contributor.authorGanoza, Silviaspa
dc.contributor.authorMontalvo, Laritzaspa
dc.contributor.authorThota, Priyaleelaspa
dc.contributor.authorLazaro, Herbertspa
dc.date.accessioned2014-06-10T00:40:22Z-
dc.date.available2014-06-10T00:40:22Z-
dc.date.issued2014-06-09-
dc.identifier.citationPLoS ONE 9(6): e99317spa
dc.identifier.doi10.1371/journal.pone.0099317-
dc.identifier.urihttp://hdl.handle.net/10757/320267-
dc.descriptionThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.eng
dc.description.abstractObjective: This study was undertaken to evaluate the association between components defining insulin resistance and breast cancer in women. Study Design: We conducted a systematic review of four databases (PubMed-Medline, EMBASE, Web of Science, and Scopus) for observational studies evaluating components defining insulin resistance in women with and without breast cancer. A meta-analysis of the association between insulin resistance components and breast cancer was performed using random effects models. Results: Twenty-two studies (n = 33,405) were selected. Fasting insulin levels were not different between women with and without breast cancer (standardized mean difference, SMD 20.03, 95%CI 20.32 to 0.27; p = 0.9). Similarly, non-fasting/ fasting C-peptide levels were not different between the two groups (mean difference, MD 0.07, 20.21 to 0.34; p = 0.6). Using individual odds ratios (ORs) adjusted at least for age, there was no higher risk of breast cancer when upper quartiles were compared with the lowest quartile (Q1) of fasting insulin levels (OR Q2 vs. Q1 0.96, 0.71 to 1.28; OR Q3 vs. Q1 1.22, 0.91 to 1.64; OR Q4 vs. Q1 0.98, 0.70 to 1.38). Likewise, there were no differences for quartiles of non-fasting/fasting C-peptide levels (OR Q2 vs. Q1 1.12, 0.91 to 1.37; OR Q3 vs. Q1 1.20, 0.91 to 1.59; OR Q4 vs. Q1 1.40, 1.03 to 1.92). Homeostatic model assessment (HOMAIR) levels in breast cancer patients were significantly higher than in people without breast cancer (MD 0.22, 0.13 to 0.31, p, 0.00001). Conclusions: Higher levels of fasting insulin or non-fasting/fasting C-peptide are not associated with breast cancer in women. HOMA-IR levels are slightly higher in women with breast cancer.eng
dc.description.sponsorshipThis study was funded by the Instituto Me´dico de la Mujer, Lima, Peru. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.eng
dc.formatapplication/pdfspa
dc.language.isoengeng
dc.publisherPublic Library of Science (PLoS)spa
dc.relation.urlhttp://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0099317spa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.subjectBreast cancereng
dc.subjectInsulineng
dc.subjectInsulin resistenceeng
dc.titleAssociation between Insulin Resistance and Breast Carcinoma: A Systematic Review and Meta-Analysisspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.identifier.eissn1932-6203-
dc.identifier.journalPLoS ONEspa
dc.description.peer-reviewRevisión por paresspa
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.